Abstract:Zhihong Liu, 1, 2, &ast Xiaofang Liang, 1, &ast Yu Zhang, 1 Wenbo Deng, 1 Yulin Wang, 3 Zhangping Lu, 2 Qianqian Liu, 2 Lianhua Wei 2 1 School of Public Health, Gansu University of Traditional Chinese Medicine, Lanzhou, Gansu, People's Republic of China; 2 Department of Clinical Laboratory, Gansu Provincial Hospital, Lanzhou, Gansu, People's Republic of China; 3 Ningxia Medical University, Yinchuan, Ningxia, People's Republic of China &astThese authors contributed equally to this work Correspondence: Lianhua Wei, Email The development of antibiotic resistance complicates the treatment of infectious diseases and is a global public health threat. However, drug repurposing can address this resistance issue and reduce research and development costs. Niclosamide is a salicylanilide compound approved by the Food and Drug Administration (FDA), and it has been used clinically for treating parasitic infections for many years. Recent studies have shown that niclosamide can inhibit bacterial and fungus activity by affecting the quorum sensing system, biofilm formation, cell membrane potential, and other mechanisms. Here, we discuss recent advances in the antimicrobial applications of niclosamide and its derivatives to provide new perspectives in treating infectious diseases. Keywords: antimicrobial resistance, multi-drug resistance, niclosamide, a derivative, drug repurposing Antibiotics have been used to treat bacterial infections for over 70 years and have been the most important class of drugs since the twentieth century. 1 However, excessive or inappropriate use of antibiotics has led to the emergence of antimicrobial resistance (AMR) and the production of multidrug-resistant (MDR) bacteria in the clinic, in animals, and even in the environment. 2 Experts estimate that AMR could force 24 million people into extreme poverty by 2030 and that MDR bacterial infections could cause 10 million deaths per year worldwide by 2050. 3 The search for new antibiotics for clinical use is becoming increasingly challenging due to the significant costs associated with drug development and the rapid emergence of drug resistance. 4 Drug repurposing is a creative strategy to address this problem. This strategy has been successfully applied to the discovery of potential treatments for a wide range of diseases, including infectious diseases. In recent years, it has been shown that, among non-antimicrobial drugs, auranofin 5 and ebselen 6 are active against many kinds of bacteria by inhibiting thioredoxin reductase (TrxR), while NIC kills microorganisms by inhibiting mechanisms such as quorum sensing systems and biofilm formation. It has attracted wide attention due to NIC's strong antibacterial activity, inhibit many kinds of bacteria, and the fact that it is not easy to develop drug resistance. NIC, a clinical antiparasitic drug approved by the FDA in 1982, works as a hydrogen ionophore that plays a role. NIC inhibits adenosine triphosphate (ATP) production through oxidative phosphorylation and uncoupling of electron transfer, leading to parasite death. 7 Over the past decades, evidence has shown that NIC can also act on other targets, such as the Wnt/β-catenin, mTOR, and JAK/STAT3 signaling pathways. 8 These pathways play an essential role in developing and progressing many diseases. The versatility of NIC has been increasingly demonstrated, while its potential in treating infectious diseases has been progressively discovered. In this paper, by searching for relevant literature in globally recognized databases such as PubMed, Web of Science, and Google Scholar. For the first time, the antibacterial and antifungal activities and mechanisms of action of NIC and its derivatives are reviewed. In addition, a brief summary of the application of NIC in other medical fields was provided. Finally, the shortcomings and perspectives of NIC and its derivatives are discussed. New ideas for the pharmaceutical reuse of NIC are provided. NIC, also known as Bayluscide, is an odorless, water-insoluble, yellowish-white crystalline powder. In the late 1950s, Bayer first discovered through screening that NIC could control Schistosoma mansoni transmission and developed and marketed it as a molluscicide. 9 In 1960, Bayer scientists discovered that it also played an essential role in controlling parasitic infections in humans. In 1962, it was marketed for human use under the trade name Yomesan. 10 The FDA added NIC to the World Health Organization (WHO) list of essential drugs in 1982. 11 Structurally, NIC belongs to a large group of lipophilic, weakly acidic molecules called salicyl -Abstract Truncated-

Niclosamide as a Promising Therapeutic Player in Human Cancer and Other Diseases

Niclosamide: Beyond an antihelminthic drug

Research advances in nicotinamide N-methyltransferase as a potential tumor biomarker

Niclosamide inhibits ovarian carcinoma growth by interrupting cellular bioenergetics

Nicotinamide N-methyltransferase Enhances the Capacity of Tumorigenesis Associated with the Promotion of Cell Cycle Progression in Human Colorectal Cancer Cells.

Optimizing Niclosamide for Cancer Therapy: Improving Bioavailability via Structural Modification and Nanotechnology

The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal Pathways.

A Blockade of IGF Signaling Sensitizes Human Ovarian Cancer Cells to the Anthelmintic Niclosamide-Induced Anti-Proliferative and Anticancer Activities

The Antifungal Potential of Niclosamide and Structurally Related Salicylanilides

Niclosamide Acts As a New Inhibitor of Vasculogenic Mimicry in Oral Cancer Through Upregulation of Mir-124 and Downregulation of STAT3.

Niclosamide inhibits colon cancer progression through downregulation of the Notch pathway and upregulation of the tumor suppressor miR-200 family

Superior Anticancer and Antifungal Activities of New Sulfanyl-Substituted Niclosamide Derivatives

The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression

Niclosamide Induces Cell Cycle Arrest in G1 Phase in Head and Neck Squamous Cell Carcinoma Through Let-7d/CDC34 Axis.

Drug Repurposing: Research Progress of Niclosamide and Its Derivatives on Antibacterial Activity

Lipid-Based Self-Microemulsion of Niclosamide Achieved Enhanced Oral Delivery and Anti-Tumor Efficacy in Orthotopic Patient-Derived Xenograft of Hepatocellular Carcinoma in Mice

Niclosamide nanoemulsion for colorectal cancer: development, physicochemical characterization, and in vitro anticancer activity

Discovery of O-Alkylamino Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents.

Antitumor effect and metabonomics of niclosamide micelles

Nicotinamide N-Methyltransferase: A Promising Biomarker and Target for Human Cancer Therapy